How is EASI calculated for dupilumab eligibility?

EASI scores severity (0–3) and extent (%) of 4 body regions (head, trunk, upper/lower limbs) for 4 signs: erythema, edema/papulation, excoriation, lichenification. Max EASI=72. Moderate AD: EASI 7.1–21; severe: >21. US FDA approval: inadequate response to topical therapies (EASI not required but IGA ≥3 typical).

How quickly does dupilumab work in atopic dermatitis?

Clinical response begins 2–4 weeks, significant improvement by week 16. SOLO 1&2 trials: 36–38% of patients achieved IGA 0/1 (clear/almost clear) at week 16 vs 8–10% placebo. EASI-50 in 52–58% at week 16. Pruritus reduction is often the earliest and most dramatic response (NRS itch score improvement within 2–4 weeks).

Dupilumab Eczema Area and Severity Assessment

Calculate EASI (Eczema Area and Severity Index) to qualify patients for dupilumab therapy (moderate-severe atopic dermatitis) and monitor treatment response. Target ≥50% EASI reduction (EASI-50).

Use the full interactive calculator below, or

Dupilumab Eczema Area and Severity Assessment

Frequently Asked Questions

How is EASI calculated for dupilumab eligibility?

How quickly does dupilumab work in atopic dermatitis?